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Several antiepileptic drugs are also being used in affective disorders. There
are some hints that also the carbonic anhydrase inhibitor acetazolamide might
be useful in the treatment of bipolar affective disorder. We report a 39-year-
old male patient with a history of bipolar affective disorder who presented
with his second manic episode. Acetazolamide was added to a low dose of
valproic acid and to perazine. A marked decrease of the BRMAS score was
achieved. The implications of this case are discussed.
.......................
Several antiepileptic drugs (AED) are also being used episode had been treated successfully with valproic acid
(VPA) and lithium. The patient had discontinued drugin affective disorders, either in the treatment of acute
mania or in the long-term prophylaxis of bipolar dis- treatment 2 or 3 months later due to intolerable weight
gain. He came to our hospital after manic symptomato-orders. There are some hints that also acetazolamide
(AZA) might be useful in the treatment of bipolar affec- logy had exacerbated 1 week ago. His main complaints
were agitation, sleep disturbances, concentration distur-tive disorder [1].
AZA is a carbonic anhydrase inhibitor that is in use bances, accelerated thinking and irritation. There were
no psychotic symptoms this time.as an AED since the 1950s [2]. Its anticonvulsant effect
correlates with the degree of inhibition of brain carbonic Three days before he came under our charge he had
been started on VPA 600 mg and perazine 400 mg. Asanhydrase. It probably acts by the increase of carbon
dioxide in the brain but also as a GABAergic agent itself. he was reluctant to take an increased dose of VPA, we
added AZA, starting with 250 mg and gradually increas-As the antiepileptic properties show tolerance after sev-
eral weeks of treatment, AZA is mainly used as an ad- ing to 1,000 mg/day. The doses of VPA and perazine were
kept unchanged. At treatment onset he had a score ofjunctive drug during periods of acute seizure exacerbation
or for the prevention of catamenial seizures. It is usually 19 on the BRMAS, gradually decreasing to 8 on day 17.
The medication was well tolerated with only transientwell tolerated although lethargy, paresthesias, rashes, ab-
dominal distention and cyanosis may appear [3]. Severe nausea, mild sedation and polyuria. Serum levels were
17.6 lg/ml on day 2 for VPA and 250 ng/ml for perazine.adverse effects might be cardiac disturbances due to loss
of electrolytes caused by polyuria. In summary, we report a patient with a manic episode
due to bipolar affective disorder who had a good responseWe report a 39-year-old male patient with a history
of bipolar affective disorder with a depressive episode to add-on therapy with AZA. Mainly two issues have to
be discussed: The patient was also on VPA which is widelywith psychotic symptoms at the age of 34 years and a
manic episode with psychotic symptoms at 38 years. This regarded as an antimanic agent. Efficacy in antimanic
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treatment, however, is not expected at the serum level of was not in a depressive but in a manic episode of a bipolar
affective disorder. As this is only a single case, further17.6 lg/ml [4]. Potentiation of the efficacy of other AED
is discussed as one mechanism of action of AZA. So, the studies on the efficacy and safety of AZA in acute mania
should be done. Other carboanhydrase inhibitors like sul-combination of AZA and VPA may have been successful
in this case. The other medication in this patient was tiam are in use as AED. To our knowledge there are no
experiences with this drug in bipolar affective disorders.perazine. Perazine as a neuroleptic agent of medium po-
tency is not seen as a powerful antimanic agent. So we do
not regard its contribution to be very high. Nevertheless,
there are still questions concerning the efficacy of AZA
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